Healthcare AI Discovery & Diagnostics Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Healthcare AI Discovery & Diagnostics Platforms
1.1 - About Healthcare AI Discovery & Diagnostics Platforms sector
Companies in Healthcare AI Discovery & Diagnostics Platforms build AI-native systems for biopharma and providers, unifying experimental, clinical, and imaging data to accelerate therapeutic discovery and clinical decision-making. They deliver computational biology engines, precision analytics, and automated workflows that reduce timelines, improve diagnostic accuracy, and surface actionable insights from real-world evidence. The category spans drug discovery, target validation, and provider-facing applications grounded in multimodal data and machine learning.
Offerings typically include closed-loop discovery platforms that automate wet-lab experiments and model genotype–phenotype relationships, target discovery using single-cell omics and functional genomics, generative protein and antibody design, and computational chemistry for lead optimization. On the clinical side, vendors provide precision oncology analytics, care pathway intelligence, radiology image analysis for fracture and chest findings, and healthcare operations automation across revenue cycle, supply chain, and EHR-integrated care management.
Primary customers include biopharma R&D organizations, hospital and health system providers, and diagnostic imaging groups. These solutions shorten time-to-target and time-to-clinic, reduce trial and discovery costs, improve diagnostic sensitivity and reporting consistency, and enhance operational efficiency and revenue capture. Buyers also benefit from better data interoperability and more reliable real-world evidence to guide portfolio decisions and care pathways.
2. Buyers in the Healthcare AI Discovery & Diagnostics Platforms sector
2.1 Top strategic acquirers of Healthcare AI Discovery & Diagnostics Platforms companies
Recursion
HQ: United States
Website
- Description: Provider of a tech-enabled drug discovery platform that unites biology, chemistry, machine learning and supercomputing to generate massive proprietary datasets, run millions of weekly wet-lab experiments and decode biological relationships, accelerating the development of new medicines.
- Key Products:
- Recursion OS: End-to-end platform that automates millions of weekly wet-lab experiments, captures multimodal biological and chemical data, and applies ML to uncover trillions of searchable relationships for target and molecule discovery
- Boltz-2 AI Model: Open-source machine-learning model that simultaneously predicts molecular structure and binding affinity with near-FEP accuracy, delivering over 1,000-fold speed and cost savings for small-molecule screening
- In-house Supercomputing Infrastructure: One of the world’s most powerful supercomputers providing massive computational scale to train large biological models and analyze proprietary datasets for faster hypothesis testing
- Phenom-2 Foundation Model: Large-scale model for cell microscopy data that distills image information to enhance transcriptomics and other downstream analyses, improving biological insight generation.
- Rationale: Provider of Recursion OS automated discovery platform, Boltz-2 binding-affinity model, and Phenom-2 microscopy model advancing drug discovery and clinical diagnostics.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Healthcare AI Discovery & Diagnostics Platforms sector
M&A buyer group 1: AI Drug Discovery
18 companies
View group →
Description: Companies in this category build software platforms that apply machine learning and computational chemistry to accelerate target identification, hit discovery, and lead optimization. Life Sciences AI Drug Discovery Platforms unify experimental and omics data, simulate molecular interactions, and prioritize candidates to reduce cycle times and R&D risk. Buyers use these tools to scale discovery pipelines, improve decision quality, and move promising assets toward preclinical validation more efficiently.
Recursion
- Type: N/A
- Employees: ●●●●●
- Description: Provider of a tech-enabled drug discovery platform that unites biology, chemistry, machine learning and supercomputing to generate massive proprietary datasets, run millions of weekly wet-lab experiments and decode biological relationships, accelerating the development of new medicines.
- Key Products:
- Recursion OS: End-to-end platform that automates millions of weekly wet-lab experiments, captures multimodal biological and chemical data, and applies ML to uncover trillions of searchable relationships for target and molecule discovery
- Boltz-2 AI Model: Open-source machine-learning model that simultaneously predicts molecular structure and binding affinity with near-FEP accuracy, delivering over 1,000-fold speed and cost savings for small-molecule screening
- In-house Supercomputing Infrastructure: One of the world’s most powerful supercomputers providing massive computational scale to train large biological models and analyze proprietary datasets for faster hypothesis testing
- Phenom-2 Foundation Model: Large-scale model for cell microscopy data that distills image information to enhance transcriptomics and other downstream analyses, improving biological insight generation.
🔒
🔒
🔒
View all 18 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Healthcare AI Discovery & Diagnostics Platforms sector
3.1 - Buyout funds in the Healthcare AI Discovery & Diagnostics Platforms sector
2.2 - Strategic buyer groups for Healthcare AI Discovery & Diagnostics Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Healthcare AI Discovery & Diagnostics Platforms companies
4.2 - Public trading comparable groups for Healthcare AI Discovery & Diagnostics Platforms sector
Valuation benchmark group 1: Biologic Drug Discovery Tools Companies
3 companies
View group →
Description: Companies in this trading comparable group are public providers of biologics-focused discovery tools and platforms. They supply recombinant proteins, antibodies, assay reagents, and custom production plus AI-enabled design services that accelerate preclinical research and therapeutic development. They are grouped as comparables given shared catalog and services revenue models, overlapping pharma and research customers, and biotech tools margin profiles, offering consistent public trading comparables for valuation.
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →